{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:01:31Z","timestamp":1776808891742,"version":"3.51.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to evaluate the safety and efficacy of dual antiplatelet pretreatment combined with low-dose rtPA therapy in patients with acute mild ischemic stroke, guided by multimodal MRI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, 383 patients with acute mild ischemic stroke (NIHSS \u2264 5) who had symptom onset within 4.5 hours of MRI screening were selected. Patients in the dual antiplatelet pretreatment plus low-dose rtPA group (164 cases) received dual antiplatelet therapy combined with low-dose (0.6 mg\/kg) rtPA intravenous thrombolysis. Patients in the standard-dose group (112 cases) received conventional-dose (0.9 mg\/kg) rtPA intravenous thrombolysis. Additionally, patients in the dual antiplatelet group who did not receive intravenous thrombolysis (107 cases) underwent 21 days of oral dual antiplatelet treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no significant difference in the baseline NIHSS scores among the three groups before treatment (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). The proportion of early neurological improvement within 24 hours and within 7 days was significantly higher in the DAPT plus low-dose group compared to both the standard-dose group and the DAPT group, with statistical significance (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). After 90 days of follow-up, the proportion of good functional outcomes in the DAPT plus low-dose group was significantly higher than in both the standard-dose group and the DAPT group (<jats:italic>p<\/jats:italic> &amp;lt; 0.05), but there was no significant difference between the standard-dose group and the DAPT group. Safety studies indicated that, under MRI guidance, the DAPT plus low-dose group and the standard-dose group had lower incidences of intracranial hemorrhage transformation and symptomatic intracranial hemorrhage, with no statistical difference among the three groups (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Mortality rates were also similar across the three groups (<jats:italic>p<\/jats:italic> &amp;gt; 0.05), with only one patient passing away in the standard-dose group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After dual antiplatelet pretreatment combined with low-dose rtPA intravenous thrombolysis for acute mild stroke under multimodal MRI guidance, the proportion of patients with good functional outcomes within 90 days was higher compared to the DAPT group and the standard-dose group, with statistical significance. There was no significant increase in the risk of cerebral hemorrhage compared to the standard-dose group and the DAPT group.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1482078","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:17:01Z","timestamp":1741187821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A study of the safety and efficacy of multi-mode NMR-guided double-antiplatelet pretreatment combined with low-dose rtPA in the treatment of acute mild ischemic stroke"],"prefix":"10.3389","volume":"16","author":[{"given":"Xia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peilan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamaneurol.2019.5061","article-title":"Distributional validity and prognostic power of the National Institutes of Health stroke scale in US administrative claims data","volume":"77","author":"Saber","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2120745","DOI":"10.1001\/jamanetworkopen.2021.20745","article-title":"Clinical characteristics, management, and in-hospital outcomes in patients with stroke or transient ischemic attack in China","volume":"4","author":"Gu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e01398","DOI":"10.1002\/brb3.1398","article-title":"Reperfusion therapy for minor stroke: a systematic review and meta-analysis","volume":"9","author":"Lan","year":"2019","journal-title":"Brain Behav"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1177\/1747493018765269","article-title":"Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health stroke scale and not clearly disabling deficits (potential of rt PA for ischemic strokes with mild symptoms PRISMS): rationale and design","volume":"13","author":"Yeatts","year":"2018","journal-title":"Int J Stroke"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1161\/STROKEAHA.120.032809","article-title":"Predictors of outcomes in patients with mild ischemic stroke symptoms: MaRISS","volume":"52","author":"Romano","year":"2021","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1161\/STROKEAHA.111.613208","article-title":"Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator, findings from get with the guidelines\u2013stroke","volume":"42","author":"Smith","year":"2011","journal-title":"Stroke"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","article-title":"Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke","volume":"374","author":"Anderson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.11.005","article-title":"\u2018Low-versus standard-dose intravenous tissue-type plasminogen activator for acute ischemic stroke\u2019: an updated meta-analysis","volume":"27","author":"Liu","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2147\/DDDT.S133759","article-title":"Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator","volume":"11","author":"Ong","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1212\/WNL.0000000000008312","article-title":"MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS","volume":"93","author":"Majidi","year":"2019","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3760\/cma.j.issn.1006-7876.2018.09.004","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018","volume":"51","year":"2018","journal-title":"Chin Soc Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early Management of Patients with Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early Management of Acute Ischemic Stroke a Guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-led trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1161\/STROKEAHA.115.009951","article-title":"Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third international stroke trial-3: post hoc analysis","volume":"46","author":"Khatri","year":"2015","journal-title":"Stroke"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e001306","DOI":"10.1161\/JAHA.114.001306","article-title":"Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke","volume":"4","author":"Choi","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e007454","DOI":"10.1161\/JAHA.117.007454","article-title":"Combining intravenous thrombolysis and antithrombotic agents in stroke: an update","volume":"7","author":"Derex","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/14737175.2019.1587295","article-title":"Effect of antiplatelet pretreatment on safety and efficacy outcomes in acute ischemic stroke patients after intravenous thrombolysis: a systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5114\/kitp.2017.68742","article-title":"The incidence of aspirin resistance in heart transplantation recipients","volume":"2","author":"Urbanowicz","year":"2017","journal-title":"Kardiochir Torakochirurgia Pol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/CIRCGENETICS.113.000303","article-title":"Cytochrome p 450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction","volume":"7","author":"Cresci","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/17474930221118900","article-title":"Early antiplatelet for minor stroke following thrombolysis (EAST): rationale and design","volume":"18","author":"Li","year":"2023","journal-title":"Int J Stroke"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/archneur.65.5.noc70077","article-title":"Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke","volume":"65","author":"Uyttenboogaart","year":"2008","journal-title":"Arch Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1161\/STROKEAHA.116.016274","article-title":"Low-versus standard-dose Alteplase in patients on prior antiplatelet therapy: the ENCHANTED trial (enhanced control of hypertension and thrombolysis stroke study)","volume":"48","author":"Robinson","year":"2017","journal-title":"Stroke"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2396987317746003","article-title":"Minor stroke due to large artery occlusion. When is intravenous thrombolysis not enough? Results from the SITS international stroke thrombolysis register","volume":"3","author":"Mazya","year":"2018","journal-title":"Eur Stroke J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3390\/brainsci11070945","article-title":"Minor non-disabling stroke patients with large vessel severe stenosis or occlusion might benefit from thrombolysis","volume":"11","author":"Zhong","year":"2021","journal-title":"Brain Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/ene.15272","article-title":"Minor stroke in large vessel occlusion: a matched analysis of patients from the German stroke registry-endovascular treatment (GSR-ET) and patients from the safe implementation of treatments in stroke-international stroke thrombolysis register (SITS-ISTR)","volume":"29","author":"Feil","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40263-024-01127-7","article-title":"TICA-CLOP STUDY: Ticagrelor versus Clopidogrel in acute moderate and moderate-to-severe ischemic stroke, a randomized controlled multi-center trial","volume":"39","author":"Ahmed","year":"2025","journal-title":"CNS Drugs"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40263-024-01080-5","article-title":"Ticagrelor versus Clopidogrel in acute large-vessel ischemic stroke: a randomized controlled single-blinded trial","volume":"38","author":"Zeinhom","year":"2024","journal-title":"CNS Drugs"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1482078\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:17:04Z","timestamp":1741187824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1482078\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":28,"alternative-id":["10.3389\/fneur.2025.1482078"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1482078","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"article-number":"1482078"}}